Zoledronic acid: Multiplicity of use across the cancer continuum

Allan Lipton

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Zoledronic acid (ZOL) has proven efficacy for reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors and bone lesions from multiple myeloma. In a head-to-head trial in patients with breast cancer, ZOL demonstrated efficacy at least comparable with, and some benefits beyond those of, pamidronate. Several studies have also demonstrated additional benefits from ZOL, including preventing bone loss, and potential anticancer activity. Adding ZOL to anticancer therapy improved disease-free and overall survival in clinical trials in women receiving adjuvant endocrine therapy for breast cancer and in patients with newly diagnosed multiple myeloma. Thus, recent advances suggest that, in addition to its established role in reducing skeletal morbidity, ZOL might also help preserve bone health in patients with early stage breast cancer. The potential role of ZOL as an anticancer therapy in this setting is the focus of intense investigation and awaits insights from ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)1001-1014
Number of pages14
JournalExpert Review of Anticancer Therapy
Issue number7
StatePublished - Jul 2011

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Zoledronic acid: Multiplicity of use across the cancer continuum'. Together they form a unique fingerprint.

Cite this